NCT04706013View on ClinicalTrials.gov

Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency

PHASE3RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 16, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Interventions
DRUG

Pyridoxal Phosphate

Oral tablets 50 mg

Trial Locations (7)

27705

ACTIVE_NOT_RECRUITING

Duke Children's Hospital, Durham

35233

RECRUITING

Children's Hospital of Alabama, Birmingham

44308

RECRUITING

Akron's Children's Hospital, Akron

80045

RECRUITING

Children's Hospital Colorado, Aurora

94304

RECRUITING

Lucile Packard Children's Hospital, Palo Alto

02115

RECRUITING

Boston Children's Hospital, Boston

Unknown

ACTIVE_NOT_RECRUITING

Queensland Children's Hospital, South Brisbane

Sponsors

Lead Sponsor

Medicure
All Listed Sponsors
lead

Medicure

INDUSTRY

NCT04706013 - Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency | Biotech Hunter | Biotech Hunter